Sign In
Buy OCUL
$8.35
+0.0400 (+0.481%)
At Close: Jun 03, 2026
Ocular Therapeutix Says Public Offering Of 8.18M Common Shares Priced At $5.50/Share
11:33am, Wednesday, 20'th May 2020Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock
11:30am, Wednesday, 20'th May 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
12:00am, Wednesday, 20'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 19)
ADC Therapeutics SA (NYSE:...
Ocular Therapeutix Announces Proposed Public Offering of Common Stock; Size Not Disclosed
08:44pm, Tuesday, 19'th May 2020Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
08:44pm, Tuesday, 19'th May 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock
12:00am, Tuesday, 19'th May 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative the
Ikarian Capital, LLC Buys Acceleron Pharma Inc, Verastem Inc, Zogenix Inc, Sells Aptose ...
12:00am, Friday, 15'th May 2020Ocular Therapeutix Announces First Patient Dosed In Phase 1 Clinical Trial Of OTX-CSI For The Treatment Of Dry Eye Disease
11:16am, Tuesday, 12'th May 2020Ocular Therapeutix™ Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease
11:00am, Tuesday, 12'th May 2020
Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, t
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, annou
H.C. Wainwright Sticks to Their Buy Rating for Ocular Therapeutix
10:52am, Monday, 11'th May 2020
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Ocular Therapeutix (NASDAQ:OCUL) on Monday, setting a price target of $10, which is approximately 67.50% above the present share price of $5.
Ocular Therapeutix (OCUL) Q1 2020 Earnings Call Transcript
03:30am, Sunday, 10'th May 2020
Good morning, everyone, and thank you for joining us on our first-quarter 2020 financial results and business update conference call. This morning, before the open, we issued a press release providin
